重新思考最佳免疫原来应对SARS-CoV-2 通过疫苗接种进化
Julià Blanco1,2,3,4, Benjamin Trinité1, Joan Puig-Barberà5
1IrsiCaixa, Badalona, Catalonia, Spain.
Influenza and other respiratory viruses
|January 28, 2025
概括
提出了针对SARS-CoV-2不断发展的受体结合域 (RBD) 的新型COVID-19疫苗助推剂. 这种策略与先进技术相结合,可以克服免疫印记并提高疫苗对新变种的有效性.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 由SARS-CoV-2引起的COVID-19大流行,对全球健康和经济产生了深远的影响.
- 目前的疫苗,主要针对完整的Spike蛋白,显示出高效率,但面临病毒演变和免疫力减弱的挑战.
- 重复接种疫苗和感染可能导致免疫印记,可能减少对随后的抗原暴露的反应.
研究的目的:
- 在病毒进化和免疫印记的背景下,探索COVID-19疫苗增压剂的最佳策略.
- 突出针对SARS-CoV-2的受体结合域 (RBD) 为增强剂疫苗开发的重要性.
- 调查减少免疫印记和最大化中和抗体反应的方法.
主要方法:
- 审查和分析有关SARS-CoV-2演变和疫苗反应的现有数据.
- 专注于受体结合域 (RBD) 作为中和抗体的关键目标.
- 考虑免疫融合和计算方法来增强疫苗策略.
主要成果:
- RBD积累了大多数SARS-CoV-2突变,因此对于向新变种至关重要.
- 免疫印记是影响反复接种疫苗或感染后免疫反应的重要因素.
- 针对提升疫苗中不断发展的RBD提供了一种有希望的方法来克服当前的局限性.
结论:
- 开发专注于SARS-CoV-2不断发展的RBD的增强剂疫苗对于长期控制COVID-19至关重要.
- 将RBD向策略与免疫融合和计算方法相结合,可能会最大限度地减少免疫印记.
- 优化增强剂策略对于增强中和免疫反应和针对SARS-CoV-2变种的整体疫苗疗效至关重要.
相关概念视频
Vaccinations
43.9K
Overview
43.9K
Cancer Vaccines
330
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
330
Viral Mutations
32.1K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
32.1K
Antigens Involved in Adaptive Immunity
446
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
446
Cross-reactivity
30.9K
Overview
30.9K
Conjugated Proteins
18.2K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
18.2K


